The association of metformin and aspirin intake with mammographic breast density: A cross-sectional study.
Caspian J Intern Med
; 14(4): 741-745, 2023.
Article
em En
| MEDLINE
| ID: mdl-38024179
ABSTRACT
Background:
Our purpose was to investigate the association between Mammographic breast density (MBD), a known strong marker for breast cancer and metformin and aspirin use and duration of use alone or simultaneously, in a sample of Iranian women considering other confounding factors.Methods:
In a cross-sectional study, 712 individuals were selected out of women referred to two university hospitals for screening mammography. Participants' information was collected with a questionnaire. Four-category density scale (a = almost entirely fatty, b = scattered fibroglandular densities, c= heterogeneously dense, and d = extremely dense) was categorized as low (a&b) and high (c&d) density.Results:
The mean age of the participants was 49.80 ± 7.26 years. Sixty-five percent of women belonged to the high and 35% to the low MBD category. Both aspirin and metformin had a significantly negative association with MBD, however, when confounding factors were entered into the models, only aspirin after adjustment for age and BMI had an inverse association with MBD (OR = 0.53, 95% CI 0.35-0.94). Simultaneous use of metformin and aspirin (OR = 0.44, 95 %CI 0.17-1.12) was associated with lower MBD. Furthermore, in women who used metformin (OR = 0.23, 95% CI 0.09-0.62) and aspirin (OR= 0.35, 95% CI 0.17-0.72) for 2 to 5 years, MBD was significantly lower. However, after the adjustment of confounding factors, these associations were not statistically significant.Conclusion:
It seems metformin and aspirin intakes are associated with MBD. However, further studies with more sample size are needed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Caspian J Intern Med
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Irã